Ideas to Action:

Independent research for global prosperity

Global Health Policy

CGD experts discuss such issues as health financing, drug resistance, clinical trials, vaccine development, HIV/AIDS, and health-related foreign assistance.

X

Global Health Policy

Feed

 

A Public Health Time Bomb

There’s a lot of attention being paid to the counterfeit drug trade at the moment. Former President of France, Jacques Chirac, recently chaired a meeting with West African leaders to discuss how to crack down on counterfeiting. Meanwhile, the Wellcome Trust and the American Pharmaceutical Group held an Opinion Formers' conference on counterfeit medicines (presentations here); the International Federation of Pharmaceutical Manufacturers and Associations produced a brief on the issue; and Roger Bate has continued to draw attention to counterfeits and other drug quality issues in developing countries, including through his book Making a Killing. And this is all on top of the WHO-hosted IMPACT initiative on counterfeits, which started in 2006.

Dispute over Pneumococcal Vaccine Initiative: A Response

An article by Ann Danaiya Usher in the December 5 edition of the Lancet focuses on aspects of the Advance Market Commitment pilot for pneumococcal vaccine that appear to be causing confusion. The article is similar to one published by the author in Development Today, a publication that has issued a series of negative (or at least skeptical) pieces about the AMC over the past few years.

Johns Hopkins Makes a New Commitment to Vaccine Access

Let's think about what decisionmakers in Ministries of Health need to know to make informed choices about what vaccines to introduce into their immunization programs, when and how. The list is long: disease burden, vaccine efficacy, costs and benefits of different introduction strategies (general or high-risk populations? routine or campaign?), financing approaches and more. And the lack of that information, available in a credible and timely way, is one of the barriers to uptake of newer vaccines.

Staging PEPFAR 2, Act I: Establishing a Policy Framework

This is a joint post with Christina Droggitis and David Wendt.

The PEPFAR Strategy

PEPFAR marked this year’s World AIDS Day (Dec 1st) with the launch of their new five-year strategy. According to the press release, this document provides a high level policy framework (not a road map or implementation plan), outlining the general direction of PEPFAR in the next five-years. More specifically the strategy provides some insight into how PEPFAR will orient its approach to treatment, care and prevention and partnerships with country governments in the fight against AIDS. Of special note are the 5 key goals and specific targets (see page 6 of the strategy) that sets PEPFAR 2 apart from the previous phase of PEPFAR in the way that policy is being articulated.

Comment on Our Drug Resistance Consultation Report

We’ve brought up the topic of drug resistance many times on this blog because we think it’s an important issue that doesn’t get enough attention. Resistance plagues the ability to successfully treat diseases in both rich and poor countries and the problem continues to grow every day. More advanced drugs that treat resistant forms of diseases cost vastly more than first-line drugs, and the cure rate is lower. Experts in drug development and disease treatment are very concerned about this problem, but those concerns have not been taken up by those who make the big decisions on global health.

Family Planning Makes a Comeback with the U.S. Global Health Initiative, But Can We Make It Stay?

Family planning is making news again. A new 12 million dollar family planning drive was launched by the U.S. government highlighting how the Obama administration’s funding has kick-started a contraception drive in Africa and other developing countries AND the International Family Planning 2009 Conference just closed in Kampala, Uganda, apparently the first such conference in 17 years! This is a sign of changing times.

How the Global Fund is Dealing with More Demand than Supply

At the Global Fund’s 20th board meeting this month in Addis Ababa, Ethiopia, the board made funding decisions for Round 9, and for the first ‘learning wave’ of their new National Strategy Applications (NSA). The NSA is an application channel where countries request funding to support strong existing national HIV/AIDS, TB, and/or Malaria strategies. There is a lot of interesting news coming out of the recent board meeting and the funding decisions, which the HIV/AIDS monitor will try to cover in a series of blogs over the coming weeks.

Pages

Tags